Orforglipron versus semaglutide: route, data, and who offers what

Same receptor family, different chemistry and schedule

Both orforglipron and semaglutide activate the GLP-1 receptor. Semaglutide is a peptide, usually injected weekly at obesity doses (2.4 mg in STEP 1 / Wegovy). Orforglipron is a non-peptide small molecule taken by mouth daily. In April 2026 the FDA approved orforglipron as Foundayo for chronic weight management in eligible adults. Semaglutide already had years of FDA-approved branded use.

This page is educational, not medical advice. Beema does not offer Foundayo. We will not claim compounded semaglutide is the best of the two. We will not run a branded-list-price versus compounded-price table.

ATTAIN-1 beside STEP 1, with caveats

STEP 1 used a reduced-calorie diet plus activity with weekly semaglutide 2.4 mg for 68 weeks in adults without diabetes. Mean weight change was about 14.9% versus 2.4% with placebo. ATTAIN-1 used healthy diet and activity (Lilly notes it was not a strict reduced-calorie protocol) with daily orforglipron for 72 weeks. Mean changes versus placebo were significant at all doses; they were smaller than STEP 1's headline mean.

If your only metric is 'largest published obesity-trial average,' weekly semaglutide 2.4 mg still sits higher. If your metric is 'FDA-approved daily tablet without injection,' orforglipron now exists as Foundayo. Those metrics answer different questions.

Daily adherence versus weekly adherence

Pills fail when days are skipped. Weekly injections fail when someone never learns the pen. Travel, shift work, and swallowing difficulties all matter. Orforglipron's lack of Rybelsus-style fasting rules is a genuine convenience point Lilly emphasized at approval. Convenience still does not erase gastrointestinal class effects.

• Orforglipron: daily tablet, small molecule, Foundayo (FDA-approved 2026), not offered by Beema
• Semaglutide obesity dose: weekly injection in STEP 1 / Wegovy, larger mean percent loss in that trial
• Beema live offering: compounded semaglutide or tirzepatide after provider review, not Foundayo

Shared class risks

Nausea, vomiting, diarrhea, and constipation appear in both programs. Discontinuation for adverse events in ATTAIN-1 was about 5.3% to 10.3% on orforglipron versus 2.7% on placebo. Semaglutide labels discuss gallbladder disease, pancreatitis warnings, pregnancy, and the thyroid C-cell boxed warning. Foundayo's Medication Guide is the document for orforglipron-specific language after approval. Read that, not a comparison blog, if you are prescribed it.

Access is not the same as a Beema cart

Foundayo is a branded product distributed through channels Lilly described at launch, including retail pharmacies. Beema's telehealth intake does not dispense it. If you want Beema's cash-pay compounded semaglutide, that is a different product with a different regulatory status: not FDA-approved, used only when legally available and clinically appropriate.

People shopping 'orforglipron research peptide' are in the wrong aisle. Orforglipron is not a peptide. Unverified capsules are not Foundayo.

How a clinician might choose

A licensed provider may weigh injection willingness, prior GLP-1 exposure, diabetes status, cardiovascular history (semaglutide 2.4 mg has SELECT data), insurance or cash-pay realities, and tolerability. This article will not pick for them. If you start Beema intake, list every GLP-1 you have tried, including pills, so the reviewer is not flying blind. A prescription is never guaranteed.

Frequently asked questions

Sources

1. [1] Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025.
2. [2] Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021.
3. [3] Eli Lilly. FDA approval of Foundayo (orforglipron). April 1, 2026.
4. [4] Wegovy (semaglutide) injection prescribing information via DailyMed.